Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KDM6A | O15550 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | TAF1 | P21675 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26948614 | 0.84 | BRD9 (0.35) | SMPD3BRD9KDM4EKDM6AKDM4A | |
| SCHEMBL12884843 | 0.82 | KDM4E (0.34) | BRD9KDM4EKDM6AKDM4ACYP2C9 | |
| SCHEMBL26381623 | 0.82 | KDM4E (0.34) | BRD9KDM4EKDM6AKDM4ACYP2C9 | |
| SCHEMBL24400469 | 0.82 | KDM4E (0.34) | BRD9KDM4EKDM6AKDM4ACYP2C9 | |
| SCHEMBL24896141 | 0.78 | SMPD3 (0.42) | SMPD3KDM4ENCF1CRHR1KDM4C | |
| SCHEMBL24879570 | 0.78 | SMPD3 (0.40) | SMPD3NCF1CRHR1KDM4CMAT2A | |
| SCHEMBL439647 | 0.76 | — | — | |
| SCHEMBL22133199 | 0.75 | SMPD3 (0.38) | SMPD3CYP2C19NCF1ADORA2AADORA1 | |
| SCHEMBL22605364 | 0.75 | SMPD3 (0.38) | SMPD3CYP2C19NCF1CRHR1DYRK1A | |
| SCHEMBL25428969 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230250127-A1 | MODIFIED mRNA 5'-CAP ANALOGS | Nanjing GeneLeap Biotechnology Co., Ltd. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230056569-A1 | ATAXIN3 (ATXN3) RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-2922859-B1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIV CORK (IE) | 2021-05-05 | — | — | EP | disclosed |
| US-9822137-B2 | Phosphonucleosides useful in the treatment of viral disorders | UNIVERSITY COLLEGE CORK (IE) | 2017-11-21 | — | — | US | disclosed |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2015-10-15 | — | — | US | disclosed |
| EP-2922859-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | University College Cork (IE) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079903-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | UNIVERSITY COLLEGE CORK (IE) | 2014-05-30 | — | — | WO | disclosed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250127-A1 | MODIFIED mRNA 5'-CAP ANALOGS | RNGTT, RNMT, NSUN2 | SMPD3 3464/4885BRD9 3194/4885KDM4E 664/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | SMPD3 1090/4885BRD9 4074/4885KDM4E 3088/4885 |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | DNAJC13, DNAJC5, DNAJC7 | SMPD3 2497/4885BRD9 1390/4885KDM4E 1635/4885 |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ADAR, SNRPE, ASGR1 | SMPD3 400/4885BRD9 3710/4885KDM4E 3902/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | SMPD3 933/4885BRD9 2230/4885KDM4E 1882/4885 |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALK, DGKG, EIF2AK2 | SMPD3 1462/4885BRD9 2446/4885KDM4E 2586/4885 |
| US-20230056569-A1 | ATAXIN3 (ATXN3) RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ATXN2, ATXN10, ATXN2L | SMPD3 14/4885BRD9 2201/4885KDM4E 4475/4885 |
| US-20150291640-A1 | PHOSPHONUCLEOSIDES USEFUL IN THE TREATMENT OF VIRAL DISORDERS | ENTPD5, PNP, MTAP | SMPD3 257/4885BRD9 4506/4885KDM4E 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.